CSPC Innovation Pharmaceutical (300765.SZ): Elected company director and general manager Yao Bing as chairman.
Xinnoway (300765.SZ) issued an announcement that the company's board of directors has received the resignation of Chairman Pan Weidong and Director Yang Dong...
CSPC Innovation Pharmaceutical (300765.SZ) announced that the Board of Directors has received the written resignation reports from the Chairman of the Board, Pan Weidong, and the Director, Yang Dong. The company held the 18th meeting of the 6th Board of Directors on September 23, 2024, and approved the proposal for the supplementary election of the Chairman of the 6th Board of Directors. In accordance with the relevant provisions of the Company Law, the Shenzhen Stock Exchange Listing Rules for Listed Companies on the GEM, normative documents, and the Company's Articles of Association, and considering the actual situation of the company, it was agreed to elect the company's Director and General Manager, Yao Bing, as the Chairman of the 6th Board of Directors, with a term from the date of approval of this Board meeting to the expiration of the term of the 6th Board of Directors.
Related Articles

CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.
CHINFMINING(01258): Regarding the tailings dam incident, Qianbi Xi wet method has already fully fulfilled the repair and governance obligations in accordance with government instructions.

A-share hot topics in the evening | NVIDIA invests $5 billion in Intel

Energizer Medicine-B (02595): Hong Kong public offering oversubscribed by 2662.79 times, net proceeds from global offering approximately 1.67 billion Hong Kong dollars.

RECOMMEND

Three-Year R&D Spend Drains RMB 2.4 Billion, Urgent Cash Needs Drive Maiwei Biotech Back to Hong Kong Amid Compliance Scrutiny
18/09/2025

Why Generating Profit Remains Challenging for Lidar Companies
18/09/2025

SEC Adopts Landmark Rule to Restrict Shareholder Class Actions in Bid to Revive IPO Market
18/09/2025